Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group

T. M. Westers; Robin Ireland; W. Kern; C. Alhan; J. S. Balleisen; P. Bettelheim; K. Burbury; M. Cullen; J. A. Cutler; M. G. Della Porta; A. M. Drager; J. Feuillard; P. Font; U. Germing; D. Haase; U. Johansson; Shahram Kordasti; M. R. Loken; L. Malcovati; J. G. te Marvelde; S. Matarraz; T. Milne; B. Moshaver; G. J. Mufti; K. Ogata; A. Orfao; A. Porwit; K. Psarra; S. J. Richards; D. Subira; V. Tindell; T. Vallespi; P. Valent; V. H. J. van der Velden; T. M. de Witte; D. A. Wells; F. Zettl; M. C. Bene; A. A. van de Loosdrecht

doi:10.1038/leu.2012.30

Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group

T. M. Westers, Robin Ireland, W. Kern, C. Alhan, J. S. Balleisen, P. Bettelheim, K. Burbury, M. Cullen, J. A. Cutler, M. G. Della Porta, A. M. Drager, J. Feuillard, P. Font, U. Germing, D. Haase, U. Johansson, Shahram Kordasti, M. R. Loken, L. Malcovati, J. G. te MarveldeS. Matarraz, T. Milne, B. Moshaver, G. J. Mufti, K. Ogata, A. Orfao, A. Porwit, K. Psarra, S. J. Richards, D. Subira, V. Tindell, T. Vallespi, P. Valent, V. H. J. van der Velden, T. M. de Witte, D. A. Wells, F. Zettl, M. C. Bene, A. A. van de Loosdrecht

Research output: Contribution to journal › Article › peer-review

229 Citations (Scopus)

Abstract

Flow cytometry (FC) is increasingly recognized as an important tool in the diagnosis and prognosis of myelodysplastic syndromes (MDS). However, validation of current assays and agreement upon the techniques are prerequisites for its widespread acceptance and application in clinical practice. Therefore, a working group was initiated (Amsterdam, 2008) to discuss and propose standards for FC in MDS. In 2009 and 2010, representatives from 23, mainly European, institutes participated in the second and third European LeukemiaNet (ELN) MDS workshops. In the present report, minimal requirements to analyze dysplasia are refined. The proposed core markers should enable a categorization of FC results in cytopenic patients as 'normal', 'suggestive of', or 'diagnostic of' MDS. An FC report should include a description of validated FC abnormalities such as aberrant marker expression on myeloid progenitors and, furthermore, dysgranulopoiesis and/or dysmonocytopoiesis, if at least two abnormalities are evidenced. The working group is dedicated to initiate further studies to establish robust diagnostic and prognostic FC panels in MDS. An ultimate goal is to refine and improve diagnosis and prognostic scoring systems. Finally, the working group stresses that FC should be part of an integrated diagnosis rather than a separate technique.

Original language	English
Pages (from-to)	1730-1741
Number of pages	12
Journal	Leukemia
Volume	26
Issue number	7
Early online date	13 Mar 2012
DOIs	https://doi.org/10.1038/leu.2012.30
Publication status	Published - Jul 2012

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/leu.2012.30

Cite this

Westers, T. M., Ireland, R., Kern, W., Alhan, C., Balleisen, J. S., Bettelheim, P., Burbury, K., Cullen, M., Cutler, J. A., Della Porta, M. G., Drager, A. M., Feuillard, J., Font, P., Germing, U., Haase, D., Johansson, U., Kordasti, S., Loken, M. R., Malcovati, L., ... van de Loosdrecht, A. A. (2012). Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group. Leukemia, 26(7), 1730-1741. https://doi.org/10.1038/leu.2012.30

@article{0b86746ca7f34734ad68c6babb91f956,

title = "Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group",

abstract = "Flow cytometry (FC) is increasingly recognized as an important tool in the diagnosis and prognosis of myelodysplastic syndromes (MDS). However, validation of current assays and agreement upon the techniques are prerequisites for its widespread acceptance and application in clinical practice. Therefore, a working group was initiated (Amsterdam, 2008) to discuss and propose standards for FC in MDS. In 2009 and 2010, representatives from 23, mainly European, institutes participated in the second and third European LeukemiaNet (ELN) MDS workshops. In the present report, minimal requirements to analyze dysplasia are refined. The proposed core markers should enable a categorization of FC results in cytopenic patients as 'normal', 'suggestive of', or 'diagnostic of' MDS. An FC report should include a description of validated FC abnormalities such as aberrant marker expression on myeloid progenitors and, furthermore, dysgranulopoiesis and/or dysmonocytopoiesis, if at least two abnormalities are evidenced. The working group is dedicated to initiate further studies to establish robust diagnostic and prognostic FC panels in MDS. An ultimate goal is to refine and improve diagnosis and prognostic scoring systems. Finally, the working group stresses that FC should be part of an integrated diagnosis rather than a separate technique.",

author = "Westers, {T. M.} and Robin Ireland and W. Kern and C. Alhan and Balleisen, {J. S.} and P. Bettelheim and K. Burbury and M. Cullen and Cutler, {J. A.} and {Della Porta}, {M. G.} and Drager, {A. M.} and J. Feuillard and P. Font and U. Germing and D. Haase and U. Johansson and Shahram Kordasti and Loken, {M. R.} and L. Malcovati and {te Marvelde}, {J. G.} and S. Matarraz and T. Milne and B. Moshaver and Mufti, {G. J.} and K. Ogata and A. Orfao and A. Porwit and K. Psarra and Richards, {S. J.} and D. Subira and V. Tindell and T. Vallespi and P. Valent and {van der Velden}, {V. H. J.} and {de Witte}, {T. M.} and Wells, {D. A.} and F. Zettl and Bene, {M. C.} and {van de Loosdrecht}, {A. A.}",

year = "2012",

month = jul,

doi = "10.1038/leu.2012.30",

language = "English",

volume = "26",

pages = "1730--1741",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Springer Nature [academic journals on nature.com]",

number = "7",

}

Westers, TM, Ireland, R, Kern, W, Alhan, C, Balleisen, JS, Bettelheim, P, Burbury, K, Cullen, M, Cutler, JA, Della Porta, MG, Drager, AM, Feuillard, J, Font, P, Germing, U, Haase, D, Johansson, U, Kordasti, S, Loken, MR, Malcovati, L, te Marvelde, JG, Matarraz, S, Milne, T, Moshaver, B, Mufti, GJ, Ogata, K, Orfao, A, Porwit, A, Psarra, K, Richards, SJ, Subira, D, Tindell, V, Vallespi, T, Valent, P, van der Velden, VHJ, de Witte, TM, Wells, DA, Zettl, F, Bene, MC & van de Loosdrecht, AA 2012, 'Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group', Leukemia, vol. 26, no. 7, pp. 1730-1741. https://doi.org/10.1038/leu.2012.30

TY - JOUR

T1 - Standardization of flow cytometry in myelodysplastic syndromes

T2 - a report from an international consortium and the European LeukemiaNet Working Group

AU - Westers, T. M.

AU - Ireland, Robin

AU - Kern, W.

AU - Alhan, C.

AU - Balleisen, J. S.

AU - Bettelheim, P.

AU - Burbury, K.

AU - Cullen, M.

AU - Cutler, J. A.

AU - Della Porta, M. G.

AU - Drager, A. M.

AU - Feuillard, J.

AU - Font, P.

AU - Germing, U.

AU - Haase, D.

AU - Johansson, U.

AU - Kordasti, Shahram

AU - Loken, M. R.

AU - Malcovati, L.

AU - te Marvelde, J. G.

AU - Matarraz, S.

AU - Milne, T.

AU - Moshaver, B.

AU - Mufti, G. J.

AU - Ogata, K.

AU - Orfao, A.

AU - Porwit, A.

AU - Psarra, K.

AU - Richards, S. J.

AU - Subira, D.

AU - Tindell, V.

AU - Vallespi, T.

AU - Valent, P.

AU - van der Velden, V. H. J.

AU - de Witte, T. M.

AU - Wells, D. A.

AU - Zettl, F.

AU - Bene, M. C.

AU - van de Loosdrecht, A. A.

PY - 2012/7

Y1 - 2012/7

N2 - Flow cytometry (FC) is increasingly recognized as an important tool in the diagnosis and prognosis of myelodysplastic syndromes (MDS). However, validation of current assays and agreement upon the techniques are prerequisites for its widespread acceptance and application in clinical practice. Therefore, a working group was initiated (Amsterdam, 2008) to discuss and propose standards for FC in MDS. In 2009 and 2010, representatives from 23, mainly European, institutes participated in the second and third European LeukemiaNet (ELN) MDS workshops. In the present report, minimal requirements to analyze dysplasia are refined. The proposed core markers should enable a categorization of FC results in cytopenic patients as 'normal', 'suggestive of', or 'diagnostic of' MDS. An FC report should include a description of validated FC abnormalities such as aberrant marker expression on myeloid progenitors and, furthermore, dysgranulopoiesis and/or dysmonocytopoiesis, if at least two abnormalities are evidenced. The working group is dedicated to initiate further studies to establish robust diagnostic and prognostic FC panels in MDS. An ultimate goal is to refine and improve diagnosis and prognostic scoring systems. Finally, the working group stresses that FC should be part of an integrated diagnosis rather than a separate technique.

AB - Flow cytometry (FC) is increasingly recognized as an important tool in the diagnosis and prognosis of myelodysplastic syndromes (MDS). However, validation of current assays and agreement upon the techniques are prerequisites for its widespread acceptance and application in clinical practice. Therefore, a working group was initiated (Amsterdam, 2008) to discuss and propose standards for FC in MDS. In 2009 and 2010, representatives from 23, mainly European, institutes participated in the second and third European LeukemiaNet (ELN) MDS workshops. In the present report, minimal requirements to analyze dysplasia are refined. The proposed core markers should enable a categorization of FC results in cytopenic patients as 'normal', 'suggestive of', or 'diagnostic of' MDS. An FC report should include a description of validated FC abnormalities such as aberrant marker expression on myeloid progenitors and, furthermore, dysgranulopoiesis and/or dysmonocytopoiesis, if at least two abnormalities are evidenced. The working group is dedicated to initiate further studies to establish robust diagnostic and prognostic FC panels in MDS. An ultimate goal is to refine and improve diagnosis and prognostic scoring systems. Finally, the working group stresses that FC should be part of an integrated diagnosis rather than a separate technique.

U2 - 10.1038/leu.2012.30

DO - 10.1038/leu.2012.30

M3 - Article

SN - 0887-6924

VL - 26

SP - 1730

EP - 1741

JO - Leukemia

JF - Leukemia

IS - 7

ER -

Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this